Price T Rowe Associates Inc. MD Sells 120,721 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Price T Rowe Associates Inc. MD lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,322,454 shares of the medical research company’s stock after selling 120,721 shares during the quarter. Price T Rowe Associates Inc. MD owned 2.57% of Charles River Laboratories International worth $358,320,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the 1st quarter worth $41,000. VisionPoint Advisory Group LLC raised its position in Charles River Laboratories International by 45.1% during the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 65 shares during the period. Brown Brothers Harriman & Co. increased its position in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 95 shares during the last quarter. Sunbelt Securities Inc. raised its stake in shares of Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 236 shares during the period. Finally, Concord Wealth Partners lifted its holdings in shares of Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after acquiring an additional 203 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Up 5.3 %

Shares of NYSE:CRL traded up $11.66 on Friday, reaching $233.47. The company had a trading volume of 646,236 shares, compared to its average volume of 451,382. The firm has a market capitalization of $12.03 billion, a PE ratio of 27.47, a PEG ratio of 2.23 and a beta of 1.38. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The firm’s 50 day simple moving average is $212.96 and its 200-day simple moving average is $230.20.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. As a group, analysts expect that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 10th. Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. TD Cowen reduced their target price on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research note on Monday, May 13th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Finally, Mizuho started coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target on the stock. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $252.29.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).